Fast Cars and No Brakes: Autologous Stem Cell Transplantation as a Platform for Novel Immunotherapies. Review uri icon

Overview

abstract

  • Autologous stem cell transplantation (ASCT) is indicated in a number of hematologic malignancies, including multiple myeloma, non-Hodgkin lymphoma, and Hodgkin lymphoma. Relapse, however, remains 1 of the main causes of post-ASCT failure, and several strategies are being investigated to decrease the risk of relapse of progression. Recent advances in the treatment of hematological malignancies have included adoptive transfer of genetically modified T cells that express chimeric antigen receptors or T cell receptors, as well the use of checkpoint inhibitors. Early clinical results in nontransplantation patients have been very promising. This review will focus on the use of gene-modified T cells and checkpoint inhibitors in stem cell transplantation.

publication date

  • October 17, 2015

Research

keywords

  • Adoptive Transfer
  • Hematologic Neoplasms
  • Receptors, Antigen, T-Cell
  • Stem Cell Transplantation
  • T-Lymphocytes

Identity

PubMed Central ID

  • PMC4706480

Scopus Document Identifier

  • 84952639840

Digital Object Identifier (DOI)

  • 10.1016/j.bbmt.2015.10.014

PubMed ID

  • 26485445

Additional Document Info

volume

  • 22

issue

  • 1